Azacitidine/Venetoclax 👍Dose modifications summary in newly diagnosed AML from Viale-A trial ✒️By Pratz #SOHO2024 #AML #AZA_VEN

Alhamdulillah! Grateful to Allah for blessing me with the SOHO Poster Award for 3rd best! Feeling truly honored by this recognition. 🙏 #SOHO2024 #Poster #ALL

😊Post transplant EBV+ PTLD 🆕️#SOHO24 ✔️NCCN Guidelines for management ✔️ECIL 6 Recommendation #SOHO2024 #Lymphoma #HCT

😊CML and TKI dosing ➡️DLT Dose limiting toxicity ➡️The right dose🤔 ➡️Dose recommendations ✒️By Cortes 👌 #SOHO2024 #CML #TKI

✅️CML and Transplantation Who, what and when 👌Excellent summary ✒️By Radich💫 #SOHO2024 #SCT #CML

👌MPN -AP/BP Myeloproliferative neoplasm accelerated phase/plastic phase ➡️Therapeutic options ➡️Treatment algorithm ✒️By Gangat #SOHO2024 #MPN #MF

At #SOHO2024: Discussing key factors and basics in High-Risk #CLL. Unmutated IGHV, complex karyotype, and TP53 aberrations are critical prognostic indicators. #Leukemia

Current PTCL Classification T cell lymphoma #SOHO24 #SOHO2024

at #SOHO2024 on diagnostic approaches in T lymphoma: 1️⃣ Nodal PTCL, NOS diagnosis excludes FHTL phenotypes & EBV+ PTCL. Biological subtypes: TBX21+, GATA3+, cytotoxic. 2️⃣ ALCL diagnosis emphasizes CD30+, EBV testing, and ALK IHC. ALK+/ALK- #Lymphoma #SOHO2024 #ALCL #PTCL

#PTCL Histology Front line therapy By Shah #SOHO2024

👌#CTCL Cutaneous T cell lymphoma 💫 ➡️Staging ➡️Skin directed therapy ➡️Systemic therapy ➡️Current clinical management ✒️By Moskowitz #SOHO24 #SOHO2024 #Lymphoma

👌Fronline treatment of follicular lymphoma conclusion 😊 #FL ✒️By Hill 🛫#SOHO24 #SOHO2024

👍Management of Relapsed/ Refractory follicular lymphoma 👍Therapeutic options ➡️POD24 Predicts poor survival ➡️Candidacy for CAR-T 🚗 Therapy ✒️By Flowers #SOHO24 #SOHO2024

🤔Follicular lymphoma ➡️Third line therapy 😌 ➡️CAR-T 🚗 ➡️Bispecific Ab for FL ➡️Treatment options flow chart ✒️By Philip #SOHO24 #SOHO2024

Shed light 🌄 on dark zone lymphoma ➡️Biology ➡️Risk for Relapse &CNS ➡️Additional therapy to RCHOP ➡️Conclusion ✅️No data to inform on whether intensification works for other dark zone lymphomas ✒️BY Scott #SOHO2024

➡️Burkitt Lymphoma Subtypes ➡️Burkitt IPI ➡️Favorable outcomes with intensive regimens ➡️Poor outcome which Improved with alloSCT in relapsed disease ✒️By Crombie #SOHO2024

➡️Algorithm for Second-line Therapy of LBCL (Relapsed/Refractory) ➡️FDA Approvals of Bispecifics in DLBCL #SOHO2024 #CART #Bispecifics

👌ECHELON-3 🆕️ is the first randomized, placebo-controlled, phase 3 study to demonstrate overall survival benefit in a contemporary population of patients with R/R DLBCL who have received 2or more prior lines of systemic therapy 💊BV+Len+R met its primary objective #SOHO2024

😊Mantle cell lymphoma (fronline) ➡️TRIANGLE 🔺️Trial Design for younger, fit pts ➡️Conclusions for Incorporating BTKi in Frontline #MCL (in older, younger, TP53) 🆕️Triplet Approach Promising for TP53,Phase 2 study of zanubrutinib, obinutuzumat, venetoclax #SOHO2024

👌Mantle cell lymphoma (Relapsed) ✅️Algorithm for Relapsed #MCL ➡️ according to BTKi exposure ✅️Relapsed-BTKi naive➡️add Ven ✅️Relapsed-BTKi exposed➡️CAR-T 🚗 approach tricks ✅️TP53➡️BOVen protocol #SOHO24